Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

Inclusion Criteria: * women ≥ 18 years of age * histologically proven early or advanced or metastatic invasive breast cancer irrespective of therapy line * ER-negative and progesterone receptor (PR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0-2+, Fluorescence In Situ Hybridization (FISH) neg.) * patients with advanced or metastatic disease must be programmed cell death ligand 1 (PD-L1)-positive (IC ≥ 1 or combined positive score (CPS) ≥ 10) in the experimental group * planned ICI therapy in combination with chemotherapy in the experimental group * written informed consent into ICK-breast Exclusion Criteria: * ER-positive or PR-positive * HER2-positive (IHC 2+, FISH pos or IHC 3+) * any systemic breast cancer therapy before inclusion into the trial for early breast cancer patients * any ICI therapy before inclusion into the trial * pregnant or lactating patients * inadequate general condition (not fit for chemotherapy)